RxDoctor Payments Data

Josefina Shen, MD

Endocrinology, Diabetes & Metabolism · Grand Rapids, MINPI 1477726917

Payments from drug & device makers

$570in general payments, 2019–2025

Across 30 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$190
  • AstraZeneca$135
  • Dexcom, Inc.$60
  • Companion Medical, Inc.$41
  • Xeris Pharmaceuticals, Inc.$35
  • Insulet Corporation$32
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$570100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk12$190
AstraZeneca4$135
Dexcom, Inc.3$60
Companion Medical, Inc.2$41
Xeris Pharmaceuticals, Inc.2$35
Insulet Corporation2$32
IBSA Pharma Inc.2$23
Medtronic1$21
Abbott1$18
Alvogen Inc1$15

How this compares

$570 in reported general payments places this provider in the 30th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan

Medicare billing

Part B allowed, 2024
$23,050
Medicare patients
141
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide38$66,749
TrulicityDulaglutide53$55,920
OzempicSemaglutide52$54,173
JardianceEmpagliflozin36$51,596
Teriparatide13$28,571
FarxigaDapagliflozin Propanediol17$26,546
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$14,279
Tresiba Flextouch U-200Insulin Degludec16$12,341
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$12,239
Humalog Kwikpen U-100Insulin Lispro31$11,008
Levothyroxine Sodium573$9,808
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$8,632
SynthroidLevothyroxine Sodium80$7,570
Novolog FlexpenInsulin Aspart18$5,690
TirosintLevothyroxine Sodium13$5,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$190$54,17352 claims
Alvogen IncTeriparatide$15$28,57113 claims
AstraZenecaFarxiga$135$26,54617 claims
IBSA Pharma Inc.Tirosint$23$5,50413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

Other endocrinology, diabetes & metabolism in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →